# Open Label Study of Long Term Safety Evaluation of Alirocumab

> **NCT01954394** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 986 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Lipid-Modifying Therapy (LMT)

## Key facts

- **NCT ID:** NCT01954394
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-17
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 986 (ACTUAL)
- **Last updated:** 2018-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954394, "Open Label Study of Long Term Safety Evaluation of Alirocumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01954394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*